Related Experiment Video
Updated: Jul 26, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events
1Department of Molecular Biology and Biochemistry, 3205 Biological Sciences II, University of California, Irvine 92697-3900, USA. atenner@uci.edu
Neurobiology of Aging
|January 5, 2002
Summary
The complement system in Alzheimer's Disease (AD) presents a dual role, potentially causing neuroinflammation while also offering neuroprotection. Understanding this balance is key to developing effective AD therapies.
Area of Science:
- Neuroimmunology
- Molecular Biology
- Pathology
Background:
- The complement system is integral to innate immunity, targeting pathogens and modulating inflammation.
- Complement activation in Alzheimer's Disease (AD) brain is linked to neuroinflammation and cognitive decline.
- Emerging evidence suggests complement components may also exert neuroprotective effects in AD.
Purpose of the Study:
- To elucidate the complex role of complement system activation in Alzheimer's Disease pathogenesis.
- To investigate the balance between pro-inflammatory and neuroprotective functions of complement in the AD brain.
- To identify molecular interactions and their consequences for neuronal function in AD.
Main Methods:
- Analysis of complement system components and their interactions in Alzheimer's Disease models.
- Investigation of cell surface receptor engagement by complement proteins.
- Assessment of the functional consequences of complement activation on neuronal health and cognitive function.
Main Results:
- Complement activation is confirmed in the Alzheimer's Disease brain, correlating with inflammatory states and cognitive impairment.
- Specific complement components demonstrate potential neuroprotective capabilities.
- The net effect on neuronal function appears to be determined by the interplay of these opposing complement activities.
Conclusions:
- The dual role of the complement system in Alzheimer's Disease, encompassing both detrimental inflammation and beneficial neuroprotection, is critical.
- Targeting the balance of complement pathways may offer novel therapeutic strategies for Alzheimer's Disease.
- Further research into specific molecular interactions is needed to design effective treatments.
More Related Videos
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:27Complement System
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...